Release No 17/2010 Changed date for interim financial report for 1st quarter 2010 Copenhagen and Oslo, May 17th, 2010 Affitech A/S has changed the date for publication of the interim financial report for 1st quarter, 2010 from May 19th 2010 to May 28th 2010. Affitech A/S's updated financial calendar is as follows: March 26th 2010: Announcement of financial results for 2009 April 29th 2010: Annual General Meeting May 28th 2010: Interim financial report for 1st quarter 2010 Aug. 26th 2010: Interim financial report for 2nd quarter 2010 Nov. 18th 2010: Interim financial report for 3rd quarter 2010 -------------------------------------------------------------------------------- | For more information please contact: | -------------------------------------------------------------------------------- | | | Affitech A/S: | | | | Dr Robert Burns, Chief Executive Officer, | | Tel # +45 5099 7642 | | Randi Krogsgaard, Corporate Communications | | Tel # +45 2320 1001 | -------------------------------------------------------------------------------- About Affitech Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.